Nuclear factor kappa B in patients with a history of unstable angina: case re-opened

This study aims at assessing NF-kB activity in unstable angina (UA) patients free of symptoms after a 1 year follow-u

Influence of crown-implant ratio on implant success rate of ultra-short dental implants: results of a 8- to 10-year retrospective study

Objectives The use of short implants has been suggested in recent years as an option for facilitating prosthetic restoration in resorbed jawbones. The aim of the present study was to determine how implant success rate is affected in the long term when ultra-short implants are rehabilitated with fixed restorations, resulting in a crown to implant (C/I) ratio of more than 3:1. Materials and methods The study was conducted as an analysis on all patients operated from December 2005 to November 2007 with ultra-short dental implants. All implants were sintered porous-surfaced (SPS) with a length of 5 mm and a diameter of 5 mm (5 x 5 mm) and were restored with a single crown or a fixed dental prosthesis (FDP). Data collected included implant positioning site, crestal bone levels (CBL), and clinical and anatomical C/I ratios, and pre-established success criteria were used to evaluate the success rate of the implants. Statistical analysis was used to determine any significant differences or correlations (p = 0.05). Results Forty-one patients completed the follow-up and were eligible for this retrospective study on a total of 50 ultra-short SPS implants. The mean follow-up was 9.5 years (range 8.3 to 10.2 years). Three of the 50 implants failed because they were lost due to peri-implantitis, while all the other 47 met the pre-established success criteria giving an overall implant success rate of 94%. During the follow-up period, the mean peri-implant bone loss (PBL) was 0.41 + 0.36 mm. Conclusions This study shows that ultra-short SPS implants can prove a reliable solution for prosthetic restoration in patients with severe alveolar bone atrophy. In selected patients with a sufficient bone width, ultra-short implants with a resulting C/I ratio of more than 3:1 presented no contraindications

Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer

IMPORTANCE Sarcopenia and sarcopenic obesity have been associated with poor outcomes in unresectable pancreatic cancer (PC). Neoadjuvant treatment (NT) is used increasingly to improve resectability; however, its effects on fat and muscle body composition have not been characterized. OBJECTIVES To evaluate whether NT affects muscle mass and adipose tissue in patients with borderline resectable PC (BRPC) and locally advanced PC (LAPC) and determine whether there were potential differences between patients who ultimately underwent resection and those who did not. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study conducted at 4 academic medical centers, 193 patients with BRPC and LAPC undergoing surgical exploration after NT who had available computed tomographic scans (both at diagnosis and preoperatively) and confirmed pancreatic ductal adenocarcinoma were evaluated. The study was conducted from January 2013 to December 2015. Data analysis was performed from September 2016 to May 2017. Measurement of body compartments was evaluated with volume assessment software before and after NT. A radiologist blinded to the patient outcome assessed the areas of skeletal muscle, total adipose tissue, and visceral adipose tissue through a standardized protocol. EXPOSURES Receipt of NT. MAIN OUTCOMES AND MEASURES Achievement of pancreatic resection at surgical exploration after the receipt of NT. RESULTS Of the 193 patients with complete radiologic imaging available after NT, 96 (49.7%) were women; mean (SD) age at diagnosis was 64 (11) years. Most patients received combined therapy with fluorouracil, irinotecan, oxaliplatin, leucovorin, and folic acid (124 [64.2%]) and 86 (44.6%) received chemoradiotherapy as well. The median interval between pre-NT and post-NT imaging was 6 months (interquartile range [IQR], 4-7 months). All body compartments significantly changed. The adipose compound decreased (median total adipose tissue area from 284.0 cm(2); IQR, 171.0-414.0 to 250.0 cm(2); IQR, 139.0-363.0; P < .001; median visceral adipose tissue area from 115.2 cm(2); IQR, 59.9-191.0 to 97.7 cm(2); IQR, 48.0-149.0 cm(2); P < .001), whereas the lean mass slightly improved (median skeletal muscle from 122.1 cm(2); IQR, 99.3-142.0 to 123 cm(2); IQR 104.8-152.5 cm(2); P =.001). Surgical resection was achievable in 136 (70.5%) patients. Patients who underwent resection had experienced a 5.9% skeletal muscle area increase during NT treatment, whereas those who did not undergo resection had a 1.7% decrease (P <.001). CONCLUSIONS AND RELEVANCE Patients with PC experience a significant loss of adipose tissue during neoadjuvant chemotherapy, but no muscle wasting. An increase in muscle tissue during NT is associated with resectabilit